Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Affini-T Therapeutics unveiled its mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
New research from Harvard University strongly suggests that infection with the Epstein-Barr virus is the leading cause of multiple sclerosis in most patients.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Former Food and Drug Commissioner Robert Califf is one step closer to returning to his old office after the Senate Health, Education, Labor and Pensions Committee advanced his nomination.
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Cardiometabolic disease is an overlooked therapeutic space that represents a huge and growing need as the global population ages, according to panelists speaking at Biotech Showcase.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.